Dr. Margaret Wall Schottstaedt, MD Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 5016 Gilmer Rd, Suite 101, Longview, TX 75604 Phone: 903-553-0035 Fax: 903-553-0065 |
News Archive
Kidney disease patients who have slower walking speed on physical performance tests seem to be more burdened by their disease than patients who perform well on lower extremity physical performance tests, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.
Scientists are reporting an advance toward development of a urine test for detecting colon cancer, the third most common cancer in the United States. Such a test could eventually compliment or even reduce the need for colonoscopy, the mainstay screening test used today. The study, which analyzes chemical differences in the urine of humans with and without colon cancer, is in ACS' Journal of Proteome Research, a monthly publication.
Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, presented its lead clinical candidate, Bendavia, during the 2011 American Heart Association's (AHA) Cardiovascular Scientific Sessions.
Reuters, in a piece exploring the issue of heroin use in Russia describes how the country's "drug problem has now become an AIDS problem."
Zila, Inc. announced that Proxy Statements and Proxies have been mailed to its stockholders in order to allow them to vote on the proposed merger with a subsidiary of TOLMAR Holding, Inc. Under the terms of the merger agreement, if approved by the stockholders, each Zila stockholder would be entitled to receive $0.45 per share in cash. Tolmar is a privately held, pharmaceutical research, development, manufacturing and commercial operations company.
› Verified 8 days ago